Here we identified B cells as a major source of rapid, innate-like production of interleukin 17 (IL-17) in vivo in response to infection with Trypanosoma cruzi. IL-17 + B cells had a plasmablast phenotype, outnumbered cells of the T H 17 subset of helper T cells and were required for an optimal response to this pathogen. With both mouse and human primary B cells, we found that exposure to parasite-derived trans-sialidase in vitro was sufficient to trigger modification of the cell-surface mucin CD45, which led to signaling dependent on the kinase Btk and production of IL-17A or IL-17F via a transcriptional program independent of the transcription factors RORgt and Ahr. Our combined data suggest that the generation of IL-17 + B cells may be a previously unappreciated feature of innate immune responses required for pathogen control or IL-17-mediated autoimmunity.
A r t i c l e s Interleukin 17 (IL-17) is a proinflammatory cytokine that contributes to host protection against a range of infectious pathogens by inducing the recruitment of neutrophils and secretion of inflammatory mediators 1 . The IL-17 family of cytokines is composed of the following six related proteins: IL-17A (IL-17), IL-17B, IL-17C, IL-17D, IL-17E (IL-25) and IL-17F. The best-studied members, IL-17A and IL-17F, share the most homology and are coordinately secreted by many subsets of cells of the immune system as homodimers or IL-17A-IL-17F heterodimers 2 .
The description of previously unknown sources of and mechanisms responsible for IL-17 production may have critical relevance to the understanding of IL-17-mediated immune responses during infection and autoimmunity. In addition to its effect on bacterial and fungal infections, IL-17 has been linked to the control of selected parasitic pathogens by emerging data [3] [4] [5] . Consistent with that theme, studies have suggested an important role for IL-17 in the resolution of infection with the protozoan parasites Trypanosoma cruzi and Trypanosoma congolense [6] [7] [8] . Indeed, published work has indicated that IL-17 exerts its protective function after exposure of mice to T. cruzi in part by recruiting suppressive IL-10-producing neutrophils that modulate interferon-γ (IFN-γ) production and thereby limit tissue damage 9 . In the absence of that IL-17-dependent response, infected mice develop more-severe liver pathology and overwhelming wasting disease.
During the course of T. cruzi infection, we observed that IL-17 was produced by various cell populations, including natural killer T cells, γδ T cells, CD4 + T cells (of the T H 17 subset of helper T cells) and CD8 + T cells 9 . Each of these cell subsets derived from the hematopoietic compartment has been identified as an IL-17-producing population 1, 10 . Notably, we also observed a predominant cell population, present during peak parasitemia, that lacked relevant lineage markers for each of these lineages. We characterized this additional cellular source of IL-17 and the signals needed to promote IL-17 production by such cells in response to infection with T. cruzi. Our data demonstrated that cells of the B lineage secreted IL-17 in response to challenge with an infectious pathogen. B cell-intrinsic production of IL-17A was triggered via a previously unknown signaling cascade in response to a T. cruzi-derived extracellular enzyme and was required for efficient control of this parasite.
RESULTS

T. cruzi infection triggers the generation of IL-17 + B cells
To identify the cell populations responsible for IL-17 production during infection with T. cruzi, we characterized the phenotype of IL-17A-producing cells in mice infected with 1 × 10 4 trypomastigotes of T. cruzi (Y strain) 11 . Unexpectedly, we found that most IL-17Aproducing cells in the spleen at day 10 after infection lacked expression of the invariant signaling protein CD3. Instead, these cells consistently expressed the prototypical B lineage cell-surface protein CD19, as well as lower amounts of the B cell antigen B220 (Fig. 1a) . Although CD4 + IL-17A-producing (T H 17) cells were generated during infection with T. cruzi, IL-17A + B220 + cells significantly outnumbered T H 17 cells at days 10 and 19 after infection ( Fig. 1b) and there was little change in the number of IL-17-producing CD8 + cells at either time point ( Fig. 1b) . Analyzing additional B cell markers, we determined that most CD19 + IL-17A + cells expressed the plasmablast or plasma-cell marker CD138 but lacked expression of the germinal center markers GL7 and PNA ( Fig. 1c and data not shown). These observations suggested that plasma cell-committed B cells, but not germinal center B cells, were able to produce IL-17. In agreement with that, immunofluorescence analysis of the spleen (Fig. 1d) identified an IL-17 + cell population with high expression of immunoglobulin M (IgM hi ) outside the (less intensely stained (IgM lo )) splenic follicle and proximal to the central arteriole (T cell zone), a finding consistent with the abundant extrafollicular plasmablast response during T. cruzi infection 12 .
To verify the results reported above, we quantified IL-17A mRNA in total splenocytes and in sorted CD19 + B220 + B cells and CD19 − B220 − non-B cells derived from infected mice. Abundant IL-17A mRNA was present after stimulation of CD19 + B220 + B cells with the phorbol ester PMA and ionomycin (Fig. 1e) . In contrast, transcripts were undetectable in B cells isolated from uninfected mice (data not shown). B220 − non-B cells from infected mice also had abundant expression of IL-17A mRNA ( Fig. 1e) , which suggested that a subset of non-B cells produced slightly more IL-17 transcripts on a per-cell basis than did B cells. Next we directly measured IL-17A in culture supernatants of purified, spleen-derived CD19 + B220 + cells from infected mice and uninfected control mice. In the absence of any additional stimulus, B cells from infected mice spontaneously secreted IL-17A, and cytokine production was further enhanced by stimulation with PMA plus ionomycin ( Fig. 1f) . We detected no IL-17A production in cultures of either stimulated B cells or resting B cells from uninfected mice.
To confirm the B cell origin of the CD19 + B220 + IL-17 + cells induced during infection with T. cruzi, we studied this population in µMT mice, which lack mature B cells. B220 + IL-17 + cells were undetectable in T. cruzi-infected µMT mice ( Fig. 1g,h) . Development of this population was restored, however, in recipients of adoptively transferred mature B cells ( Fig. 1g,h) . IL-17 + cells induced in B cell-reconstituted, infected µMT mice had a surface phenotype indistinguishable from that observed in infected wild-type mice (B220 dim CD19 + CD138 + GL7 − PNA − IL-17 + cells; Fig. 1g ). Together these results demonstrated that B cells were able to secrete the proinflammatory cytokine IL-17A in response to challenge with an infectious pathogen. Furthermore, these B cell production of IL-17A promotes control of T. cruzi To assess the physiological relevance of IL-17 production by B cells during infection with T. cruzi, we adoptively transferred wild-type or IL-17A-deficient B cells into µMT mice and infected the recipient mice with T. cruzi. Although equivalent B cell reconstitution was achieved in all recipient mice ( Supplementary Fig. 1 ), µMT mice and µMT recipients of IL-17A-deficient B cells had more parasitemia than did µMT recipients of wild-type B cells ( Fig. 2a ) and, ultimately, this led to accelerated mortality ( Fig. 2b) . Lack of B cell production of IL-17A was associated with higher concentrations of IFN-γ and tumor-necrosis factor ( Fig. 2c,d ). Those differences correlated with more tissue damage, as manifested by higher concentrations of transaminases ( Fig. 2e) . Thus, B cells were the main producers of IL-17A during acute infection with T. cruzi, and B cell-intrinsic production of IL-17A was critical for the protective response to this pathogen.
B cells use alternative IL-17-triggering signals
We next determined the signals that led to B cell production of IL-17 during infection with T. cruzi. The cytokines IL-23 and IL-6 strongly promote IL-17 production by γδ T cells and CD4 + T cells 1, 10 . Unexpectedly, we found similar numbers of B220 + IL-17 + cells in infected wild-type mice and in infected mice deficient in the receptor for IL-23 (IL-23R) or deficient in IL-6 ( Supplementary Fig. 2a ), which indicated that signaling via IL-23 or IL-6 was not required for B cell production of IL-17A. Further, B cell-T cell cooperation through the costimulatory receptor CD40 pathway 13 was also not required, as we detected in similar numbers of IL-17-producing B220 + cells in infected CD40-deficient mice and infected wild-type control mice ( Supplementary Fig. 2a ).
Microbial products that trigger C-type lectin receptors and Tolllike receptors (TLRs) promote IL-17 production by innate cells 10 . Moreover, TLR ligands are critically involved in the activation and differentiation of B cells 14, 15 and mediate recognition of T. cruzi by the immune system 16 . Thus, we analyzed whether direct triggering of TLRs or the B cell antigen receptor (BCR) induced IL-17 production by purified B cells in vitro. We detected little or no IL-17 production in culture supernatants of normal splenic B cells stimulated with various doses of zymosan (dectin-1; TLR2 ligand), lipopolysaccharide (LPS; TLR4 ligand), the dinucleotide CpG (TLR9 ligand), antibody to IgM (anti-IgM), or CpG plus anti-IgM ( Supplementary Fig. 2b ), which indicated that crosslinking of TLRs or BCRs or both was insufficient to induce potent IL-17 production. Consistent with those data, we observed no defect in the generation of B220 + IL-17 + B cells in infected µMT mice that were recipients of adoptively transferred mature B cells lacking MyD88, a key adaptor required for TLR signaling (data not shown).
T. cruzi triggers the generation of IL-17 + B cells in vitro
As T. cruzi is a complex microorganism that initiates a cascade of direct and indirect lineage-specific activation events in vivo 16 , we determined whether in vitro exposure to this parasite was sufficient to initiate IL-17 production by purified B cells. Indeed, live T. cruzi trypomastigotes rapidly induced parasite dose-dependent production of IL-17A by follicular mature B cells ( Fig. 3a and data not shown). Similarly, antigen from total homogenates of T. cruzi trypomastigotes induced detectable, albeit less, secretion of IL-17A by total splenic B cells ( Fig. 3a) . Of note, we confirmed the purity (>90-95%) and phenotype of flow cytometry-sorted B cells in this and all subsequent experiments. npg Notably, in highly purified splenic B cell subsets, mature (marginal zone or follicular) B cells secreted both IL-17A and IL-17F after exposure to live parasites, but immature (transitional) B cells did not (Fig. 3b,c) . Lack of cytokine expression by transitional B cells was not due to less cell viability (data not shown). Notably, neither total spleen cells from lymphopenic mice (deficient in recombination-activating gene 2) nor wild-type non-B cells or purified T cells produced IL-17A after stimulation with T. cruzi in vitro ( Supplementary Fig. 2c,d) , which indicated that a contaminating non-B cell or non-T cell population or residual T cells did not account for IL-17 production in response to parasite encounter.
Additionally, we evaluated the participation of key B cell surface proteins in triggering IL-17 production in vitro. Consistent with our in vivo data, cytokine production was not altered by loss of the costimulatory receptor CD40 or the TLR signaling adaptor MyD88. We also observed no effect on IL-17 production by restricting BCR specificity to the recognition of a non-parasite-associated antigen (hen-egg lysozyme; Supplementary Fig. 2e ). Thus, direct exposure of B cells to T. cruzi trypomastigotes was sufficient to initiate B cell production of IL-17.
T. cruzi trans-sialidase drives the formation of IL-17 + B cells
Polyclonal B cell activation is a hallmark of acute infection with T. cruzi 17, 18 , which indicates that a range of T. cruzi surface antigens might be able to trigger an IL17 program. We noted that IL-17Aproducing B cells were most abundant at peak parasitemia, a time point that coincides with strong polyclonal B cell activation. Therefore, we investigated whether candidate polyclonal activators expressed on the surface of T. cruzi might be sufficient to trigger B cell production of IL-17. We focused our efforts on T. cruzi trans-sialidase, an abundant, glycosylphosphatidylinositol-anchored enzyme on the parasite cell surface required for parasite invasion 19 , shown before to have potent T cell-independent B cell-mitogenic activity 20 . Notably, recombinant, enzymatically active trans-sialidase efficiently triggered dose-dependent production of IL-17A by mouse B cells (Fig. 3d) .
T. cruzi trans-sialidase is composed of an amino-terminal catalytic domain and a long carboxy-terminal domain containing of multiple 12-amino acid tandem repeats (with the sequence DSSAHSTPSTPA), also known as the shed acute-phase antigen (SAPA) 21 . Trans-sialidase activity is critical for the pathogenesis of T. cruzi 22, 23 , and a natural point substitution (replacement of the tyrosine at position 342 with histidine (Y342H)) in trans-sialidase that abrogates its enzymatic activity while retaining its amino-terminal lectin-like activity prevents many immunological alterations induced by trans-sialidase in vivo 23 . In contrast, strong antigenicity 21 and B cell-mitogenic activity 20 is present in the SAPA motifs of the carboxy-terminal moiety. We therefore analyzed IL-17A secretion after stimulating B cells with recombinant Y342H-mutant trans-sialidase. Although the mutant trans-sialidase was still able to trigger some IL-17A production, this cytokine production was significantly lower than that stimulated by active trans-sialidase ( Fig. 3d) , which indicated that enzymatic activity was required for a robust response and that either the SAPA repeats or residual amino-terminal lectin activity may have partially mediated the cytokine production. To further assess the role of SAPA repeats, we used a neutralizing monoclonal antibody (mAb) directed against the catalytic site of trans-sialidase 22, 24 ; this reagent blocks both the enzymatic function and residual lectin activity of trans-sialidase. Treatment with the mAb to trans-sialidase abrogated trans-sialidase-or trypomastigote-induced production of IL-17, but treatment with control mAb did not ( Fig. 3e) , which indicated that trans-sialidase was the sole T. cruzi molecule required for this process.
Glycoconjugate remodeling promotes B cell secretion of IL-17
Trans-sialidase has a unique enzymatic activity, first described in trypanosomatids, that promotes the transfer of α(2,3)-linked sialic acid from host glycoconjugates to acceptor proteins on the parasite surface or to recipient host molecules 25 . In the absence of suitable acceptors, trans-sialidase also has neuraminidase activity that leads to the hydrolysis of α(2,3)-linked sialyl residues 26 . We evaluated the role of these alternative enzymatic activities in IL-17 secretion IL-17A (pg/ml) 2,500 2,000 1,500 1,000 500 
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A r t i c l e s by B cells in our experimental system. We first assessed whether IL-17A production was induced after hydrolysis of sialyl residues with neuraminidases derived from various candidate bacterial species, including Vibrio cholerae (specific for α(2,3)-linked sialyl residues) and Clostridium perfringens (able to hydrolyze α(2,3)-, α(2,6)and α(2,8)-linked sialyl residues). We detected no IL-17A after stimulating B cells with various doses of bacterial neuraminidases ( Fig. 3f and data not shown), which suggested that desialylation of B cell-surface molecules was not sufficient to trigger of IL-17 production. Because trans-sialidase is able to sialylate lymphocyte membrane proteins in vivo 26 , and protein specific sialylation is associated with alterations in immunological function 27, 28 , we assessed whether transsialidase-catalyzed modification of host B cell-surface molecules might promote IL-17 production. For this, we cultured B cells with bovine serum albumin (BSA) under serum-free conditions to avoid the presence of soluble donor or acceptors of sialyl residues. We detected production of IL-17 in the presence of trans-sialidase or parasites only when the sialyl donor α(2,3)-sialyl-lactose was present, but not when the control sugar, α(2,6)-sialyl-lactose was present (Fig. 3g) ; this linked sialylation of B cells with IL-17A production.
To better mimic physiological conditions, in which serum glycoproteins act not only as donors but also as suitable residue acceptors, we did experiments in which we added lactose as a sialyl residue acceptor. Under these conditions, the production of IL-17 was considerably enhanced (Fig. 3g) . Together these data supported the idea that the simple acquisition of sialyl residues on the B cell triggered modest IL-17 secretion, whereas the more complete surface glycoconjugate remodeling that occurs in the presence of sialyl donor or acceptor molecules promoted a vigorous IL-17 response program.
The generation of IL-17 + B cells requires cell-surface mucin CD45
Trans-sialidase has been reported to catalyze the sialylation of host acceptor molecules, including the tyrosine phosphatase CD45, on the surface of T lymphocytes 25 . Although this has not been directly tested before, such events have been postulated to promote the immunological abnormalities induced by trans-sialidase. As an initial screen for a potential role for CD45 in the B cell IL-17 program, we used a CD45-specific inhibitor (N-(9,10-dioxo-9,10-dihydro-phenanthren-2-yl)-2,2-dimethyl-propionamide). We observed significantly less production of IL-17A and IL-17F when we incubated sorted B cells with T. cruzi trypomastigotes and increasing doses of that inhibitor (Fig. 4a, Supplementary Fig. 3a and data not shown).
Next we assessed the genetic requirement for CD45 in the in vitro IL-17 effector response through the use of B cells isolated from CD45deficient mice. In contrast to wild-type B cells, CD45-deficient B cells did not produce IL-17A or 17F in response to exposure to the parasite T. cruzi ( Fig. 4a and Supplementary Fig. 3a) . Furthermore, in contrast to their wild-type counterparts, CD45-deficient B cells adoptively transferred into recipient µMT mice were unable to restore the B220 + IL-17 + population generated after infection with T. cruzi (Fig. 4b,c) .
Galectins are sugar-binding proteins that participate in many immune responses 29 , and binding of galectin-1 and galectin-3 to CD45 can modulate the survival of T lymphocytes 30 . These lectins are produced by B cells in response to infection with T. cruzi 31, 32 and might recognize sialylation changes induced by trans-sialidase. The induction of IL-17 by this parasite, however, was unimpaired by B cell-intrinsic loss of galectin-1 or galectin-3 (Fig. 4d) , which ruled out the possibility of a role for these lectins in these events.
B cell production of IL-17 requires Src and Btk kinases
We next addressed the potential intracellular signaling pathways that lead to B cell production of IL-17. Consistent with the key role for CD45 in regulating the activity of the Src family of kinases, inhibition of Src with the Src inhibitor PP2 resulted in considerable attenuation of IL-17 production in trypomastigote-stimulated B cells ( Fig. 4e and  Supplementary Fig. 3b ). As published work has linked the non-receptor tyrosine kinase Btk to trans-sialidase-mediated B cell-mitogenic activity 33 , we investigated whether the kinases Btk or Tec or other downstream Btk effectors, including PKC-β and NF-κB 34, 35 , were required for IL-17 production. The addition of specific, covalent inhibitors of Btk-Tec (AVL-292 or CNX-652) resulted in much less production of IL-17A and abrogated production of IL-17F ( Fig. 4f  and Supplementary Fig. 3c ). In agreement with that, we detected little or no IL-17 after activating B cells derived from Btk-deficient mice with trypomastigotes, and IL-17 production was abrogated in parasite-stimulated B cells deficient in both Btk and Tec ( Fig. 4f and  Supplementary Fig. 3c ). Of note, deletion of Btk kinases or the addition of various inhibitors of Btk had no appreciable effect on B cell survival in these assays (data not shown). Consistent with those findings, Btk-deficient mice had considerably fewer CD19 + IL-17 + B cells than did wild-type mice after in vivo infection with T. cruzi (Fig. 4g) .
Notably, IL-17 production by B cells cultured with T. cruzi was not affected by deficiency in the key Btk effector PKC-β (Fig. 4h) . PKC-β signaling is essential for BCR-driven activation of NF-κB. Consistent with the lack of requirement for PKC-β, pharmacological inhibition of NF-κB also had no effect on IL-17 production ( Supplementary   Fig. 4a ). Together these results demonstrated that T. cruzi triggered a signaling cascade dependent on CD45, Src kinases, Btk and Tec that initiated B cell-specific production of IL-17.
B cells do not use the 'canonical' IL-17 program
The transcription factor RORγt is essential for the differentiation of naive T cells into T H 17 cells and subsequent IL-17 expression 2, 36 . Studies have also demonstrated a requirement for RORγt in all IL-17-producing lineages, including 'innate' IL-17 + cells 10 . On the basis of those data, we evaluated the requirement for RORγt in B cell production of IL-17. Unexpectedly, we found that RORγt-deficient and wild-type B cells stimulated with either T. cruzi trypomastigotes or trans-sialidase produced similar concentrations of IL-17A and IL-17F (Fig. 5a) . Consistent with the requirement for trans-sialidase in those events, IL-17 production was blocked in both populations by the addition of the mAb to trans-sialidase ( Fig. 5a) .
RORα, a nuclear receptor related to RORγt, can act in synergy with RORγt to promote development of the T H 17 lineage. We stimulated purified wild-type B cells with trypomastigotes in the presence or absence of the RORα-and RORγt-specific inhibitor SR1001 and observed no effect on B cell production of IL-17 (Fig. 5b) . The liganddependent transcription factor Ahr also promotes development of the T H 17 lineage and production of IL-17 and the T H 17 cytokine IL-22 (ref. 37) . Purified, trypomastigote-stimulated Ahr-deficient and wildtype B cells generated similar amounts of IL-17A (Fig. 5b) . In concert with those in vitro data, infection with T. cruzi led to equivalent numbers of CD19 + IL-17 + B cells in RORγt-deficient, Ahr-deficient and wild-type mice (Fig. 5c) .
As an alternative means of addressing the role of RORγt in the processes noted above, we did immunofluorescence studies of spleens from uninfected and T. cruzi-infected RORγt-red fluorescent protein (RFP) reporter mice. Although all T cells expressed the RFP reporter 38 because of transient expression of RORγt during thymocyte development 39 , we did not identify IgM + RFP + B cells after infection (Fig. 5d) . Consistent with those findings and the intact CD19 + IL-17 + response in T. cruzi-infected IL-23R-deficient or IL-6-deficient mice (Supplementary Fig. 2a) , IL-17 production in B cells stimulated in vitro was unaffected by B cell-intrinsic loss of IL-6 or combined absence of both the receptor for IL-21 and IL-23R ( Supplementary  Fig. 4b ). Together these results demonstrated that exposure to T. cruzi 
T. cruzi promotes human B cell production of IL-17
To determine whether the signaling cascade noted above was operational in primary human B cells in response to T. cruzi, we studied purified human tonsillar CD19 + B cells in vitro. We cultured cells in medium alone or with recombinant human IL-10 or the B cell cytokine BAFF, to facilitate cell survival, and concurrently stimulated the cells with T. cruzi trypomastigotes. Human IL-17 production was consistently triggered in response to parasite exposure (Fig. 6) . In contrast to their abundance in mouse B cells, IL-17F was slightly more abundant than IL-17A. IL-17F was detectable in cultures supernatants stimulated with parasites alone, and this was potentiated by the addition of IL-10 or BAFF. We detected IL-17A only in cultures stimulated with the parasite and supplemented with IL-10 or BAFF. Notably, consistent with our findings obtained with mouse B cells, IL-17 production was abrogated by the addition of mAb to trans-sialidase. Furthermore, the addition of CD45-or Btk-specific inhibitors resulted in significantly less IL-17 production. Cell viability was improved in cultures containing IL-10 or BAFF, and the addition of Btk inhibitors had no appreciable effect on survival (data not shown). Thus, T. cruzi transsialidase drove IL-17 production in human B cells via a CD45-and Btkdependent signaling program analogous to that in mouse B cells.
DISCUSSION
Our findings here have identified B cells as a chief source of rapid, innate-like production of IL-17 in response to infection with T. cruzi. IL-17 + B cells were present at the time of peak parasitemia and outnumbered T H 17 cells throughout the course of infection. Notably, acute infection with T. cruzi was associated with polyclonal B cell activation and, congruent with that response, IL-17 + B cells had a plasmablast phenotype (CD19 + B220 dim GL7 − CD138 + ). Thus, our data suggest that in addition to antibody secretion, IL-17 production may represent an additional key effector function for plasma cells in this infection. Consistent with that idea, B cell-intrinsic production of IL-17A was required for efficient control of parasitemia and regulation of parasite inflammatory responses. Notably, B cell production of IL-17 in response to T. cruzi trypomastigotes occurred via a previously unknown pathway triggered by parasite-derived trans-sialidase.
Our data support a model whereby this enzyme directly modifies the B cell surface protein CD45 (or indirectly effects CD45 activity through modification of another B cell surface protein) and thereby triggers intracellular signaling dependent on Src and the Btk-Tec family of kinases. Such signals ultimately drive abundant IL-17 production via a transcriptional program independent of RORγt and Ahr. Notably, this signaling program operated in both mouse primary B cells and human primary B cells. Genetic deletion or pharmacological blockade of CD45 abrogated B cell production of IL-17. Thus, specific alterations in the structure or localization of CD45 unique to trans-sialidase-modified B cells seem to be directly or indirectly required for the initiation of IL-17 production. The receptor-like tyrosine phosphatase CD45 is expressed on all nucleated hematopoietic cells and is one of the most abundant cell-surface glycoproteins. CD45 has an essential role in signal transduction through BCRs and T cell antigen receptors and also modulates signaling from integrin and cytokine receptors by controlling the relative threshold of sensitivity to external stimuli 40 . Notably, the activity of CD45 is precisely regulated by the structural features of its extracellular domain. Distinct lymphoid populations express specific CD45 isoforms by alternative splicing of exons encoding regions of the extracellular domain. Developing and activated lymphocytes also differ in the extent of glycosylation of the extracellular domain as well as site-specific O-and N-glycan sialylation, and such microheterogenous changes effect cell survival and activation 41 . Notably, in contrast to results obtained with B cells, exposure of primary T cells to T. cruzi trypomastigotes did not trigger IL-17 production, despite published evidence of trans-sialidase-mediated modification of CD45 on T cells 25 . Similarly, trypomastigote-stimulated myeloid cells and neutrophils also did not generate IL-17. Thus, trans-sialylation of CD45 (or of molecules that interact with CD45) on B cells probably functions to initiate signaling. Both the enzymatic and residual amino-terminal lectin activity of trans-sialidase, but not the repetitive carboxy-terminal SAPA motifs, were required for maximal B cell production of IL-17 in vivo. These findings suggest that transsialidase triggers a unique manner of CD45 compartmentalization or oligomerization that initiates the IL-17 transcriptional program. This program operated independently of key candidate receptors on the B cell surface, including CD40 and MyD88-dependent innate receptors. CD45 oligomerization may explain why these events did not require antigen-specific recognition by the BCR. However, whether this program requires the scaffolding function of an intact BCR, integrins or other receptors on the B cell surface remains to be determined. Notably, unlike mature B cells, purified transitional B cells did not respond to T. cruzi trypomastigotes (or trans-sialidase), which indicates that a B cell stage-specific CD45 isoform or a mature transcriptional development program 42 is essential for these events.
CD45 modulates signal-transduction thresholds as a positive or negative regulator of kinases of the Src family, with its dominant activity dependent on its precise localization. Through the use of inhibitors and genetic models, we have demonstrated a requirement for both Src and Btk-Tec kinases in this pathway B cells. On the basis of published work 43 , we hypothesize that trans-sialylation of CD45 initiates Src kinase-dependent trans-phosphorylation of the activation loop tyrosine in Btk-Tec kinases. Activated Btk is able to directly trans-phosphorylate a wide range of signaling effectors, including PLC-γ2, adaptors and transcription factors 34, 44 . Unexpectedly, IL-17 production did not require the Btk-dependent essential BCR downstream effectors PKC-β and NF-κB. Future studies should identify proximal signaling intermediates modified in response to exposure to trans-sialidase in primary B cells through the use of high-sensitivity mass-spectroscopy.
The nuclear receptors and transcription factors RORγt and RORα serve essential roles in the IL-17 program in T H 17 cells, CD8 + cells and innate IL-17-producing cells, including γδ T cells, invariant natural killer T cells, natural killer cells and lymphoid tissue-inducer-like cells 2, 10, 36 . In naive T cells, initial and sustained expression of RORγt is coordinately controlled by signaling inputs from key environmental cytokines (IL-1, IL-6, TGF-β, IL-21 and IL-23) that mediate activation of the transcription factor STAT3 and the interaction of additional transcription factors. Other effectors, including Ahr, also function to sustain IL-17 production in RORγt-expressing cells. Thus, one of the most unexpected findings of our study was that the generation of IL-17 + B cells occurred independently of the expression or activity of RORγt, RORα and Ahr and, similarly, that the B cell IL-17 program was unimpeded by lack of IL-6, IL-21 or IL-23R. Notably, although neutrophils are also capable of IL-17 production 45 , it remains unknown whether these cells require RORγt, which raises the possibility that other innate cells might use RORγt-independent programs for IL-17 production. Our findings set the stage for assays designed to identify proximal effectors and nuclear factors required for B cell transcription of the gene encoding IL-17; such work may provide new insight into the biology of this cytokine family.
In summary, our findings have demonstrated that B cells were driven to rapidly secrete IL-17A and IL-17F in response to challenge with an infectious pathogen and that IL-17 + B cells were a chief source of this cytokine during infection with T. cruzi. Our data leave several questions unanswered. Most notably, our observations suggest that the generation of IL-17 + B cells may be an unappreciated feature of the innate immune response required for pathogen control in other disease settings. In this context, several bacterial species, including Streptococcus pneumoniae, Campylobacter jejuni and Pasteurella multocida, also express trans-sialidases [46] [47] [48] [49] . Furthermore, both cells of the B lineage and IL-17 have been linked to a range of autoimmune disorders. Indeed, low, chronic T. cruzi infection leads to life-threatening chronic inflammatory sequelae that represent a major disease burden in parasite-endemic regions 50 . Thus, it will be useful to determine the role(s) of IL-17 + B cells in this clinically important setting as well as in candidate autoimmune disorders.
METHODS
Methods and any associated references are available in the online version of the paper.
